SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology ($GSIT) is trending due to news highlighting their Compute-In-Memory APU achieving GPU-class AI performance with significantly lower energy costs, sparking community interest in its potential to compete with industry giants like NVDA. Discussions revolve around the APU's performance and energy efficiency, with some viewing GSIT as an overlooked player in the AI and drone sectors due to its exposure to high-speed memory solutions and defense contracts.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending after announcing plans to explore rare earth production at its U.S. mining sites, potentially making it a key player in America's push for critical mineral independence. The community is discussing the company's strategic shift from steel to strategic minerals, with some believing it's a smart move given China's tightening export controls, while others express skepticism and focus on debt reduction.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

REPL is experiencing a surge driven by news of the FDA accepting the resubmission of its Biologics License Application for RP1, a melanoma treatment. Community members are actively discussing price target upgrades and the potential for a short squeeze, while also weighing the possibility of future dilution. The stock's movement is also being compared to other trending tickers in the sector.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending due to positive data released by partner GenFleet Therapeutics regarding their lung cancer drug GFH375, showing promising response rates in NSCLC patients. The community is discussing the potential implications of these results, including a possible short squeeze, buyout scenarios, and comparing VSTM to competitors like RVMD. There is optimism regarding upcoming catalysts, such as presentations, NCCN decisions, and potential partnerships.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix ($CRMD) is trending after reporting preliminary Q3 results and raising FY25 revenue guidance, leading to a surge in stock price. The community is actively discussing the company's profitability, potential for a short squeeze, and a possible acquisition by Pfizer. Positive real-world evidence and further catalysts are anticipated, while some investors express frustration with management decisions.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity (CELC) is trending following positive Phase 3 trial data for its breast cancer therapy, with the community actively discussing the potential for FDA approval and a possible buyout. The stock's significant pre-market surge has sparked conversations about its valuation and future prospects in the biotech sector. Community members are weighing the potential for continued gains against the possibility of a pullback.

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.

RAPT Therapeutics Inc

RAPT Therapeutics is trending following the announcement of positive topline data from its Phase 2 trial of RPT904 in Chronic Spontaneous Urticaria, leading to discussions about potential price targets and the strength of the biotech momentum. However, some community members are expressing concerns about potential offerings and drops, while others remain optimistic about the company's future and potential breakouts. The stock is also being mentioned in connection with other trending stocks and potential squeeze opportunities.

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Exelixis Inc

Exelixis is trending due to discussions around unusual options activity and potential bullish setups, including a possible short squeeze due to high short interest. Community members are also focused on the company's long-term potential, driven by its commercial product and pipeline updates, with some viewing it as a possible acquisition target. Recent analyst ratings and target price adjustments are contributing to the increased attention on the stock.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Corbus Pharmaceuticals Holdings Inc

CRBP is trending following a significant drop, despite positive analyst ratings and insider buying, leading to speculation about market manipulation and a potential overreaction to news from a competitor in the weight loss space. The community is actively discussing the disconnect between the stock's performance and its strong fundamentals, including a promising drug pipeline and substantial cash reserves. Upcoming presentations and data releases related to their oncology programs are anticipated catalysts that could shift the stock's trajectory.

Guggenheim Strategic Opportunities Fund operates as a diversified, closed-end management investment company. The fund intends to maximize total return through a combination of current income and capital appreciation. It pursues a relative value-based investment philosophy, which utilizes quantitative and qualitative analysis to seek to identify securities or spreads between securities that deviate from their perceived fair value and/or historical norms. The company was founded on November 13, 2006 and is headquartered in Chicago, IL.

Guggenheim Strategic Opportunities Fund

GOF is trending as investors discuss its recent price drop and high dividend yield. The fund's sustainability is being questioned due to its distribution strategy and sensitivity to interest rates, while others are viewing the dip as a buying opportunity, reinvesting dividends at a discount. The community is actively monitoring its premium to NAV and potential impacts from broader market conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
